AtriCure (ATRC) Financials

$33.26 -0.79 (-2.32%)

Closing price 05/21/2025 04:00 PM Eastern

Extended Trading

$33.26 0.00 (0.00%)

As of 05/21/2025 05:07 PM Eastern

Annual Income Statements for AtriCure

This table shows AtriCure's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-45	-30	-46	50	-48	-35	-21	-27	-33	-27	-16
Consolidated Net Income / (Loss)	-45	-30	-46	50	-48	-35	-21	-27	-33	-27	-16
Net Income / (Loss) Continuing Operations	-45	-30	-46	50	-48	-35	-21	-27	-33	-27	-16
Total Pre-Tax Income	-44	-30	-46	50	-48	-35	-21	-27	-33	-27	-16
Total Operating Income	-40	-27	-43	55	-44	-33	-17	-25	-31	-27	-16
Total Gross Profit	348	300	246	206	149	170	147	126	111	93	76
Total Revenue	465	399	330	274	207	231	202	175	155	130	107
Operating Revenue	465	399	330	274	207	231	202	175	155	130	107
Total Cost of Revenue	118	99	84	68	57	60	55	49	44	37	32
Operating Cost of Revenue	118	99	84	68	57	60	55	49	44	37	32
Total Operating Expenses	388	327	289	151	194	203	164	151	142	120	92
Selling, General & Admin Expense	291	253	231	205	151	167	130	117	106	94	74
Research & Development Expense	96	74	57	49	43	41	35	34	36	26	19
Total Other Income / (Expense), net	-3.66	-3.16	-3.53	-4.82	-3.81	-1.87	-3.78	-1.90	-2.16	-0.46	0.18
Interest Expense	7.77	6.93	4.99	4.92	4.89	4.11	4.61	2.26	1.80	0.29	0.31
Interest & Investment Income	4.43	3.79	1.99	0.47	1.10	2.40	1.01	0.23	0.23	0.19	0.10
Other Income / (Expense), net	-0.33	-0.03	-0.54	-0.37	-0.02	-0.16	-0.18	0.14	-0.59	-0.35	0.39
Income Tax Expense	1.02	0.59	0.27	0.19	0.11	0.20	0.23	0.01	0.04	0.04	0.03
Basic Earnings per Share	($0.95)	($0.66)	($1.02)	$1.11	($1.14)	($0.94)	($0.62)	($0.83)	($1.05)	($0.97)	($0.61)
Weighted Average Basic Shares Outstanding	46.97M	46.31M	45.74M	45.07M	42.13M	37.59M	34.09M	32.39M	31.61M	28.06M	26.37M
Diluted Earnings per Share	($0.95)	($0.66)	($1.02)	$1.09	($1.14)	($0.94)	($0.62)	($0.83)	($1.05)	($0.97)	($0.61)
Weighted Average Diluted Shares Outstanding	46.97M	46.31M	45.74M	46.04M	42.13M	37.59M	34.09M	32.39M	31.61M	28.06M	26.37M
Weighted Average Basic & Diluted Shares Outstanding	48.88M	95.18M	93.14M	46.03M	42.13M	37.59M	34.09M	32.39M	31.61M	28.06M	26.37M

This table shows AtriCure's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-6.75	-16	-7.85	-8.01	-13	-9.79	-9.06	-5.12	-6.48	-4.17	-12
Consolidated Net Income / (Loss)	-6.75	-16	-7.85	-8.01	-13	-9.79	-9.06	-5.12	-6.48	-4.17	-12
Net Income / (Loss) Continuing Operations	-6.75	-16	-7.85	-8.01	-13	-9.79	-9.06	-5.12	-6.48	-4.17	-12
Total Pre-Tax Income	-6.51	-15	-7.53	-7.76	-13	-9.42	-9.01	-5.03	-6.40	-4.05	-12
Total Operating Income	-5.95	-15	-7.41	-7.17	-11	-8.67	-8.09	-4.14	-5.78	-4.14	-11
Total Gross Profit	93	93	87	87	81	80	74	77	70	65	62
Total Revenue	124	124	116	116	109	107	98	101	93	88	83
Operating Revenue	124	124	116	116	109	107	98	101	93	88	83
Total Cost of Revenue	31	32	29	29	28	27	24	24	24	23	22
Operating Cost of Revenue	31	32	29	29	28	27	24	24	24	23	22
Total Operating Expenses	99	107	94	94	92	88	82	81	75	69	72
Selling, General & Admin Expense	76	72	73	74	72	68	62	64	60	56	57
Research & Development Expense	23	35	21	20	20	21	20	17	15	14	15
Total Other Income / (Expense), net	-0.55	-0.78	-0.13	-0.59	-2.17	-0.75	-0.92	-0.88	-0.62	0.09	-1.50
Interest Expense	1.42	1.45	1.67	1.61	3.04	1.80	1.77	1.72	1.64	1.56	1.32
Interest & Investment Income	1.04	1.20	1.28	1.00	0.95	1.04	0.92	0.96	0.88	1.43	0.37
Other Income / (Expense), net	-0.18	-0.53	0.26	0.03	-0.08	0.01	-0.06	-0.12	0.15	0.22	-0.55
Income Tax Expense	0.24	0.27	0.32	0.25	0.18	0.37	0.05	0.09	0.08	0.12	0.05
Basic Earnings per Share	($0.14)	($0.33)	($0.17)	($0.17)	($0.28)	($0.21)	($0.20)	($0.11)	($0.14)	($0.10)	($0.27)
Weighted Average Basic Shares Outstanding	47.39M	46.97M	47.11M	46.91M	46.72M	46.31M	46.41M	46.27M	46.11M	45.74M	45.82M
Diluted Earnings per Share	($0.14)	($0.33)	($0.17)	($0.17)	($0.28)	($0.21)	($0.20)	($0.11)	($0.14)	($0.10)	($0.27)
Weighted Average Diluted Shares Outstanding	47.39M	46.97M	47.11M	46.91M	46.72M	46.31M	46.41M	46.27M	46.11M	45.74M	45.82M
Weighted Average Basic & Diluted Shares Outstanding	49.50M	48.88M	48.75M	48.70M	48.38M	95.18M	47.40M	47.35M	47.24M	93.14M	-

This table details how cash moves in and out of AtriCure's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	38	26	14	1.71	13	-3.75	10	-2.40	0.44	-4.62	13
Net Cash From Operating Activities	12	4.48	-22	-14	-20	-16	-4.17	-8.94	-15	-7.84	-22
Net Cash From Continuing Operating Activities	12	4.48	-22	-14	-20	-16	-4.17	-8.94	-15	-7.84	-22
Net Income / (Loss) Continuing Operations	-45	-30	-46	50	-48	-35	-21	-27	-33	-27	-16
Consolidated Net Income / (Loss)	-45	-30	-46	50	-48	-35	-21	-27	-33	-27	-16
Depreciation Expense	11	9.46	8.06	7.53	7.87	7.42	7.24	7.76	7.66	4.98	3.35
Amortization Expense	8.10	6.47	5.64	6.15	3.43	1.40	1.66	1.66	1.99	1.94	2.03
Non-Cash Adjustments To Reconcile Net Income	54	36	29	110	23	18	17	15	13	9.85	8.20
Changes in Operating Assets and Liabilities, net	-16	-17	-18	-188	-5.65	-7.41	-8.66	-6.08	-4.11	2.60	-19
Net Cash From Investing Activities	30	22	44	24	-156	-2.15	-85	3.76	-12	-11	-31
Net Cash From Continuing Investing Activities	30	22	44	24	-156	-2.15	-85	3.76	-12	-11	-31
Purchase of Property, Plant & Equipment	-11	-12	-17	-9.75	-5.26	-12	-6.21	-6.38	-7.69	-13	-5.51
Acquisitions	-12	-30	0.00	0.00	-	-17	0.00	0.00	-	-7.58	0.00
Purchase of Investments	0.00	0.00	-25	-173	-227	-73	-107	-16	-29	-20	-41
Sale of Property, Plant & Equipment	0.03	0.00	0.00	-	-	0.04	0.01	0.00	0.00	0.00	0.08
Sale and/or Maturity of Investments	54	64	86	206	75	100	27	27	24	41	20
Net Cash From Financing Activities	-3.60	-0.03	-7.06	-7.64	189	14	100	2.76	28	14	66
Net Cash From Continuing Financing Activities	-3.60	-0.03	-7.06	-7.64	189	14	100	2.76	28	14	66
Repayment of Debt	-64	-1.05	-0.90	-6.99	-0.70	-0.33	-2.89	-0.05	-0.56	-0.33	-6.56
Issuance of Debt	61	0.00	0.00	5.00	0.00	20	17	0.00	25	0.00	0.00
Issuance of Common Equity	5.06	5.26	4.23	4.18	192	2.66	85	2.11	1.62	1.54	67
Other Financing Activities, net	-5.93	-4.24	-10	-9.84	-2.19	-7.96	0.43	0.70	1.64	13	5.28
Effect of Exchange Rate Changes	-0.42	-0.06	-0.36	-0.37	0.14	-0.16	-0.18	0.02	-0.05	-0.24	-0.16
Cash Interest Paid	5.95	6.38	4.27	4.22	4.37	3.72	3.87	2.00	1.51	0.23	0.12
Cash Income Taxes Paid	0.62	0.40	0.19	0.19	0.22	0.26	0.07	0.04	0.03	0.02	0.15

This table details how cash moves in and out of AtriCure's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-23	-7.61	24	41	-19	3.71	13	-10	19	9.28	-5.73
Net Cash From Operating Activities	-11	5.84	20	7.38	-21	4.03	1.52	3.01	-4.08	0.05	-1.78
Net Cash From Continuing Operating Activities	-11	5.84	20	7.38	-21	4.03	1.52	3.01	-4.08	0.05	-1.78
Net Income / (Loss) Continuing Operations	-6.75	-16	-7.85	-8.01	-13	-9.79	-9.06	-5.12	-6.48	-4.17	-12
Consolidated Net Income / (Loss)	-6.75	-16	-7.85	-8.01	-13	-9.79	-9.06	-5.12	-6.48	-4.17	-12
Depreciation Expense	2.97	2.94	3.04	2.64	2.59	2.48	2.41	2.36	2.21	2.18	2.02
Amortization Expense	2.23	2.00	2.01	1.95	2.15	1.99	1.99	1.47	1.03	1.07	1.39
Non-Cash Adjustments To Reconcile Net Income	9.63	22	10	10	11	9.31	8.66	9.00	8.76	7.20	7.00
Changes in Operating Assets and Liabilities, net	-19	-5.93	12	0.41	-23	0.04	-2.48	-4.69	-9.60	-6.23	0.08
Net Cash From Investing Activities	-1.68	-15	4.39	31	9.64	-2.79	12	-16	29	7.00	-3.24
Net Cash From Continuing Investing Activities	-1.68	-15	4.39	31	9.64	-2.79	12	-16	29	7.00	-3.24
Purchase of Property, Plant & Equipment	-2.18	-2.69	-3.61	-2.38	-2.77	-2.79	-3.63	-3.08	-2.50	-4.17	-5.15
Sale and/or Maturity of Investments	0.00	-	8.00	33	12	-	16	17	31	11	23
Other Investing Activities, net	0.50	-	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	-10	1.74	-0.33	2.85	-7.86	2.36	0.13	2.99	-5.52	1.98	-0.41
Net Cash From Continuing Financing Activities	-10	1.74	-0.33	2.85	-7.86	2.36	0.13	2.99	-5.52	1.98	-0.41
Repayment of Debt	-0.29	-0.28	-0.34	-0.41	-63	-0.26	-0.25	-0.24	-0.30	-0.24	-0.23
Issuance of Debt	0.00	-	-	-	61	-	-	-	0.00	-	-
Other Financing Activities, net	-10	-3.05	0.00	3.26	-6.15	-2.64	0.38	3.24	-5.22	-2.01	-0.18
Effect of Exchange Rate Changes	0.20	-0.50	0.24	-0.06	-0.11	0.11	-0.17	-0.03	0.03	0.25	-0.31
Cash Interest Paid	1.25	2.35	1.43	1.45	0.73	1.66	1.64	1.59	1.49	1.34	1.13
Cash Income Taxes Paid	0.12	0.04	0.07	0.49	0.02	0.17	0.07	0.17	-0.01	0.06	0.00

This table presents AtriCure's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	609	614	585	615	715	558	357	268	276	273	158
Total Current Assets	268	266	215	196	307	143	175	82	86	75	94
Cash & Equivalents	123	84	58	44	42	28	32	22	24	24	28
Short-Term Investments	0.00	53	63	75	202	53	92	13	20	11	31
Accounts Receivable	60	53	43	33	23	28	25	23	21	19	18
Inventories, net	75	68	46	39	35	29	22	22	18	18	14
Prepaid Expenses	9.43	8.56	5.48	5.00	4.35	3.90	2.59	2.27	-	-	-
Plant, Property, & Equipment, net	0.00	0.00	39	0.00	28	33	27	29	30	31	12
Total Noncurrent Assets	342	348	331	419	380	382	155	157	161	167	53
Goodwill	235	235	235	235	235	235	105	105	105	105	35
Intangible Assets	56	64	39	43	128	130	49	51	52	54	8.88
Other Noncurrent Operating Assets	50	49	5.77	37	2.35	4.74	0.50	0.68	0.32	0.32	0.19
Total Liabilities & Shareholders' Equity	609	614	585	615	715	558	357	268	276	273	158
Total Liabilities	148	148	129	132	302	311	107	107	108	86	26
Total Current Liabilities	73	75	58	56	49	50	40	32	29	32	26
Short-Term Debt	2.81	2.53	5.47	-	-	-	-	-	1.69	0.45	-
Accounts Payable	25	27	20	19	13	15	9.66	12	11	13	7.62
Accrued Expenses	46	45	33	36	28	33	26	19	16	18	14
Total Noncurrent Liabilities	75	73	70	75	253	261	67	75	79	55	0.22
Long-Term Debt	62	61	57	60	53	60	36	24	24	0.00	-
Other Noncurrent Operating Liabilities	13	13	4.32	15	189	189	19	38	42	41	0.15
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	461	466	457	484	412	247	249	161	168	187	133
Total Preferred & Common Equity	461	466	457	484	412	247	249	161	168	187	133
Total Common Equity	461	466	457	484	412	247	249	161	168	187	133
Common Stock	864	824	787	765	742	530	497	387	368	353	271
Retained Earnings	-402	-357	-327	-280	-330	-282	-247	-226	-199	-166	-138
Accumulated Other Comprehensive Income / (Loss)	-1.04	-0.99	-4.10	-0.95	0.31	-0.16	-0.20	0.03	-0.47	-0.61	-0.35

This table presents AtriCure's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023
Total Assets	592	615	597	592	600	594	583
Total Current Assets	251	269	253	245	253	238	238
Cash & Equivalents	100	130	106	65	81	67	77
Accounts Receivable	63	55	56	55	52	48	46
Inventories, net	75	77	74	72	62	55	49
Prepaid Expenses	13	7.50	9.61	12	6.28	7.18	7.96
Plant, Property, & Equipment, net	41	44	42	42	41	41	40
Total Noncurrent Assets	299	302	302	304	306	316	305
Goodwill	235	235	235	235	235	235	235
Intangible Assets	54	58	60	62	66	67	39
Other Noncurrent Operating Assets	9.77	9.11	7.23	7.46	5.69	5.89	6.23
Total Liabilities & Shareholders' Equity	592	615	597	592	600	594	583
Total Liabilities	137	150	135	135	137	132	128
Total Current Liabilities	61	74	61	61	83	71	62
Accounts Payable	25	32	27	29	25	24	24
Accrued Expenses	33	40	32	30	37	32	28
Other Current Liabilities	2.84	2.72	2.54	2.54	21	16	11
Total Noncurrent Liabilities	76	76	74	74	55	60	66
Long-Term Debt	62	62	62	62	42	47	52
Other Noncurrent Operating Liabilities	14	14	12	12	13	13	14
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	455	465	462	456	463	462	455
Total Preferred & Common Equity	455	465	462	456	463	462	455
Total Common Equity	455	465	462	456	463	462	455
Common Stock	863	851	841	827	812	803	791
Retained Earnings	-409	-386	-378	-370	-347	-338	-333
Accumulated Other Comprehensive Income / (Loss)	-0.23	-0.15	-0.57	-0.70	-2.18	-2.61	-3.07

This table displays calculated financial ratios and metrics derived from AtriCure's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	16.55%	20.84%	20.43%	32.83%	-10.52%	14.47%	15.40%	12.64%	19.54%	20.75%	31.22%
EBITDA Growth	-94.95%	63.46%	-143.07%	307.87%	-34.75%	-191.12%	45.50%	30.17%	-9.54%	-90.49%	-21.49%
EBIT Growth	-51.00%	38.17%	-178.79%	223.91%	-32.98%	-92.27%	30.32%	21.70%	-17.18%	-69.54%	-46.59%
NOPAT Growth	-49.96%	37.47%	-154.31%	277.63%	-33.55%	-93.39%	31.43%	19.78%	-16.53%	-63.33%	-50.22%
Net Income Growth	-46.85%	34.49%	-192.56%	204.24%	-36.83%	-66.50%	21.40%	19.34%	-22.51%	-67.86%	-41.43%
EPS Growth	-43.94%	35.29%	-193.58%	195.61%	-21.28%	-51.61%	25.30%	20.95%	-8.25%	-59.02%	-8.93%
Operating Cash Flow Growth	172.17%	120.25%	-60.67%	30.65%	-25.67%	-279.07%	53.37%	40.84%	-92.80%	63.69%	-313.63%
Free Cash Flow Firm Growth	29.37%	15.73%	-40.11%	-86.00%	66.43%	-253.63%	-1.93%	12.00%	79.19%	-270.02%	29.86%
Invested Capital Growth	2.78%	10.24%	11.10%	46.55%	-2.62%	29.85%	5.59%	2.03%	1.11%	147.48%	42.60%
Revenue Q/Q Growth	3.96%	4.86%	4.69%	5.99%	-1.71%	3.79%	3.51%	2.89%	3.53%	5.23%	7.54%
EBITDA Q/Q Growth	-39.23%	-48.38%	22.25%	8.69%	-5.86%	-100.14%	-9.47%	27.31%	11.68%	-29.98%	2.96%
EBIT Q/Q Growth	-18.84%	-21.57%	16.92%	9.46%	-5.23%	-60.68%	-3.33%	19.47%	7.49%	-24.58%	-3.35%
NOPAT Q/Q Growth	-17.14%	-20.46%	16.39%	10.11%	-5.18%	-62.34%	-2.83%	18.21%	8.61%	-28.04%	0.36%
Net Income Q/Q Growth	-14.85%	-22.64%	17.08%	10.62%	-5.40%	-56.22%	-4.19%	18.35%	6.42%	-25.74%	-2.30%
EPS Q/Q Growth	-14.46%	-20.00%	15.00%	13.54%	1.72%	-59.32%	0.00%	18.63%	9.48%	-25.97%	8.96%
Operating Cash Flow Q/Q Growth	17.37%	796.80%	-1.17%	-36.07%	27.36%	-39.96%	-14.97%	7.90%	24.25%	-35.79%	4.64%
Free Cash Flow Firm Q/Q Growth	19.74%	85.78%	-122.20%	8.93%	14.18%	-10.57%	13.49%	-3.25%	80.63%	-659.43%	55.73%
Invested Capital Q/Q Growth	1.61%	5.39%	0.00%	-3.10%	-4.67%	-2.19%	-1.86%	0.22%	-2.55%	137.56%	-3.58%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	74.69%	75.23%	74.44%	75.04%	72.29%	73.80%	72.97%	72.21%	71.63%	71.58%	70.50%
EBITDA Margin	-4.52%	-2.70%	-8.93%	24.98%	-15.96%	-10.60%	-4.17%	-8.83%	-14.24%	-15.54%	-9.85%
Operating Margin	-8.60%	-6.68%	-12.92%	20.12%	-21.42%	-14.35%	-8.49%	-14.30%	-20.07%	-20.59%	-15.23%
EBIT Margin	-8.67%	-6.69%	-13.08%	19.99%	-21.43%	-14.42%	-8.59%	-14.22%	-20.45%	-20.87%	-14.86%
Profit (Net Income) Margin	-9.61%	-7.62%	-14.06%	18.30%	-23.32%	-15.25%	-10.48%	-15.39%	-21.49%	-20.97%	-15.09%
Tax Burden Percent	102.34%	101.98%	100.58%	99.63%	100.24%	100.57%	101.08%	100.05%	100.12%	100.13%	100.20%
Interest Burden Percent	108.27%	111.73%	106.93%	91.88%	108.55%	105.15%	120.80%	108.20%	104.96%	100.38%	101.31%
Effective Tax Rate	0.00%	0.00%	0.00%	0.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-7.05%	-5.00%	-8.84%	20.43%	-13.99%	-11.68%	-7.13%	-10.80%	-13.67%	-16.80%	-21.01%
ROIC Less NNEP Spread (ROIC-NNEP)	18.20%	8.42%	3.69%	23.11%	1.85%	12.40%	17.51%	318.92%	50.02%	0.81%	-11.11%
Return on Net Nonoperating Assets (RNNOA)	-2.60%	-1.60%	-1.04%	-9.22%	-0.61%	-2.49%	-3.17%	-5.52%	-5.10%	-0.25%	5.21%
Return on Equity (ROE)	-9.64%	-6.60%	-9.88%	11.20%	-14.60%	-14.17%	-10.30%	-16.32%	-18.78%	-17.05%	-15.80%
Cash Return on Invested Capital (CROIC)	-9.79%	-14.74%	-19.35%	-17.33%	-11.34%	-37.65%	-12.57%	-12.80%	-14.78%	-101.69%	-56.13%
Operating Return on Assets (OROA)	-6.60%	-4.45%	-7.20%	8.25%	-6.96%	-7.28%	-5.54%	-9.13%	-11.55%	-12.55%	-11.81%
Return on Assets (ROA)	-7.31%	-5.08%	-7.74%	7.55%	-7.57%	-7.70%	-6.77%	-9.88%	-12.13%	-12.61%	-11.99%
Return on Common Equity (ROCE)	-9.64%	-6.60%	-9.88%	11.20%	-14.60%	-14.17%	-10.30%	-16.32%	-18.78%	-17.05%	-15.80%
Return on Equity Simple (ROE_SIMPLE)	-9.70%	-6.53%	-10.17%	10.38%	-11.68%	-14.23%	-8.48%	-16.69%	-19.79%	-14.58%	-12.23%
Net Operating Profit after Tax (NOPAT)	-28	-19	-30	55	-31	-23	-12	-17	-22	-19	-11
NOPAT Margin	-6.02%	-4.68%	-9.04%	20.05%	-14.99%	-10.05%	-5.95%	-10.01%	-14.05%	-14.41%	-10.66%
Net Nonoperating Expense Percent (NNEP)	-25.25%	-13.41%	-12.53%	-2.68%	-15.84%	-24.08%	-24.64%	-329.71%	-63.69%	-17.62%	-9.90%
Return On Investment Capital (ROIC_SIMPLE)	-5.33%	-3.53%	-5.65%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	25.31%	24.77%	25.56%	24.96%	27.71%	26.20%	27.03%	27.79%	28.37%	28.42%	29.50%
SG&A Expenses to Revenue	62.62%	63.40%	70.00%	74.60%	73.03%	72.42%	64.24%	66.96%	68.61%	72.33%	68.41%
R&D to Revenue	20.67%	18.51%	17.35%	17.68%	20.85%	17.86%	17.22%	19.54%	23.10%	19.84%	17.31%
Operating Expenses to Revenue	83.29%	81.92%	87.36%	54.92%	93.71%	88.15%	81.46%	86.51%	91.70%	92.17%	85.72%
Earnings before Interest and Taxes (EBIT)	-40	-27	-43	55	-44	-33	-17	-25	-32	-27	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-21	-11	-30	69	-33	-24	-8.40	-15	-22	-20	-11
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.23	3.63	4.51	6.60	6.08	5.20	4.73	3.90	3.86	3.87	4.14
Price to Tangible Book Value (P/TBV)	8.78	10.10	11.28	15.50	50.72	0.00	12.43	122.22	58.85	26.14	6.21
Price to Revenue (P/Rev)	3.20	4.24	6.24	11.64	12.14	5.57	5.85	3.60	4.19	5.57	5.10
Price to Earnings (P/E)	0.00	0.00	0.00	63.62	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	1.57%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.55	4.13	5.51	9.47	10.59	5.63	6.38	3.86	4.01	4.38	7.49
Enterprise Value to Revenue (EV/Rev)	3.08	4.05	5.93	11.05	11.20	5.47	5.47	3.61	4.14	5.35	4.47
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	44.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	55.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	55.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	117.33	360.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.14	0.14	0.16	0.12	0.16	0.29	0.19	0.23	0.23	0.08	0.00
Long-Term Debt to Equity	0.13	0.13	0.14	0.12	0.16	0.29	0.19	0.23	0.22	0.07	0.00
Financial Leverage	-0.14	-0.19	-0.28	-0.40	-0.33	-0.20	-0.18	-0.02	-0.10	-0.30	-0.47
Leverage Ratio	1.32	1.30	1.28	1.48	1.93	1.84	1.52	1.65	1.55	1.35	1.32
Compound Leverage Factor	1.43	1.45	1.37	1.36	2.09	1.94	1.84	1.79	1.62	1.36	1.34
Debt to Total Capital	12.30%	11.93%	13.53%	10.99%	13.51%	22.40%	16.07%	18.61%	18.76%	7.05%	0.06%
Short-Term Debt to Total Capital	0.53%	0.48%	1.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.81%	0.22%	0.00%
Long-Term Debt to Total Capital	11.77%	11.45%	12.49%	10.99%	13.51%	22.40%	16.07%	18.61%	17.94%	6.83%	0.06%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	87.70%	88.07%	86.47%	89.01%	86.49%	77.60%	83.93%	81.39%	81.24%	92.95%	99.94%
Debt to EBITDA	-3.08	-5.85	-2.42	0.87	-1.95	-2.92	-5.68	-2.39	-1.76	-0.70	-0.01
Net Debt to EBITDA	2.76	6.88	3.43	-2.39	5.89	0.94	9.12	-0.16	0.37	1.40	6.47
Long-Term Debt to EBITDA	-2.94	-5.62	-2.24	0.87	-1.95	-2.92	-5.68	-2.39	-1.68	-0.68	-0.01
Debt to NOPAT	-2.31	-3.38	-2.39	1.09	-2.08	-3.08	-3.98	-2.11	-1.78	-0.76	-0.01
Net Debt to NOPAT	2.07	3.97	3.39	-2.98	6.27	0.99	6.39	-0.14	0.37	1.50	5.98
Long-Term Debt to NOPAT	-2.21	-3.24	-2.21	1.09	-2.08	-3.08	-3.98	-2.11	-1.71	-0.73	-0.01
Altman Z-Score	6.03	6.94	9.47	14.94	4.85	2.19	6.48	2.93	3.04	4.51	12.36
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.65	3.57	3.69	3.47	6.24	2.87	4.34	2.58	2.97	2.37	3.65
Quick Ratio	2.49	2.55	2.81	2.69	5.44	2.20	3.72	1.80	2.26	1.71	3.01
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-39	-55	-65	-47	-25	-75	-21	-21	-24	-113	-31
Operating Cash Flow to CapEx	106.73%	37.37%	-131.16%	-141.29%	-377.81%	-130.21%	-67.22%	-140.10%	-196.63%	-58.33%	-397.72%
Free Cash Flow to Firm to Interest Expense	-5.01	-7.96	-13.11	-9.49	-5.14	-18.18	-4.59	-9.16	-13.08	-387.66	-100.30
Operating Cash Flow to Interest Expense	1.57	0.65	-4.44	-2.80	-4.07	-3.85	-0.91	-3.95	-8.39	-26.86	-70.82
Operating Cash Flow Less CapEx to Interest Expense	0.10	-1.09	-7.83	-4.79	-5.14	-6.80	-2.25	-6.77	-12.66	-72.90	-88.63
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.76	0.67	0.55	0.41	0.32	0.50	0.65	0.64	0.56	0.60	0.79
Accounts Receivable Turnover	8.25	8.39	8.73	9.77	8.07	8.67	8.35	7.91	7.66	7.02	6.89
Inventory Turnover	1.64	1.74	1.99	1.85	1.78	2.33	2.43	2.42	2.49	2.31	2.59
Fixed Asset Turnover	0.00	0.00	0.00	0.00	6.78	7.73	7.22	5.95	5.06	6.06	12.50
Accounts Payable Turnover	4.50	4.19	4.39	4.37	4.13	4.92	4.94	4.20	3.76	3.62	3.91
Days Sales Outstanding (DSO)	44.26	43.51	41.82	37.37	45.24	42.10	43.70	46.15	47.66	51.99	53.01
Days Inventory Outstanding (DIO)	221.93	210.10	183.49	197.22	205.52	156.62	150.44	150.77	146.47	157.94	140.86
Days Payable Outstanding (DPO)	81.17	87.22	83.20	83.52	88.29	74.26	73.96	86.84	97.11	100.78	93.40
Cash Conversion Cycle (CCC)	185.02	166.40	142.11	151.07	162.46	124.46	120.18	110.07	97.01	109.15	100.47
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	403	392	356	320	218	224	173	164	160	159	64
Invested Capital Turnover	1.17	1.07	0.98	1.02	0.93	1.16	1.20	1.08	0.97	1.17	1.97
Increase / (Decrease) in Invested Capital	11	36	36	102	-5.87	52	9.15	3.25	1.77	94	19
Enterprise Value (EV)	1,432	1,617	1,959	3,030	2,312	1,263	1,102	631	642	695	480
Market Capitalization	1,490	1,692	2,060	3,194	2,506	1,286	1,179	629	651	723	548
Book Value per Share	$9.46	$9.84	$9.99	$10.53	$9.16	$6.25	$6.47	$4.68	$5.07	$5.79	$4.82
Tangible Book Value per Share	$3.48	$3.53	$3.99	$4.48	$1.10	($2.97)	$2.46	$0.15	$0.33	$0.86	$3.21
Total Capital	526	529	528	543	477	319	297	198	207	201	133
Total Debt	65	63	71	60	64	71	48	37	39	14	0.07
Total Long-Term Debt	62	61	66	60	64	71	48	37	37	14	0.07
Net Debt	-58	-74	-101	-164	-194	-23	-77	2.41	-8.12	-28	-68
Capital Expenditures (CapEx)	11	12	17	9.75	5.26	12	6.21	6.38	7.69	13	5.43
Debt-free, Cash-free Net Working Capital (DFCFNWC)	74	57	41	21	13	11	10	16	15	9.04	8.22
Debt-free Net Working Capital (DFNWC)	197	194	162	140	258	93	134	50	59	44	68
Net Working Capital (NWC)	194	192	157	140	258	93	134	50	57	43	68
Net Nonoperating Expense (NNE)	17	12	17	4.80	17	12	9.15	9.41	12	8.51	4.76
Net Nonoperating Obligations (NNO)	-58	-74	-101	-164	-194	-23	-77	2.41	-8.12	-28	-68
Total Depreciation and Amortization (D&A)	19	16	14	14	11	8.82	8.91	9.42	9.64	6.92	5.39
Debt-free, Cash-free Net Working Capital to Revenue	16.01%	14.26%	12.46%	7.49%	6.48%	4.96%	4.99%	9.10%	9.39%	6.96%	7.65%
Debt-free Net Working Capital to Revenue	42.38%	48.64%	49.12%	50.90%	124.73%	40.40%	66.69%	28.82%	37.77%	33.61%	63.16%
Net Working Capital to Revenue	41.78%	48.01%	47.47%	50.90%	124.73%	40.40%	66.69%	28.82%	36.68%	33.27%	63.16%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.95)	($0.66)	($1.02)	$1.11	($1.14)	($0.94)	($0.62)	($0.83)	($1.05)	($0.97)	($0.61)
Adjusted Weighted Average Basic Shares Outstanding	46.97M	46.31M	45.74M	45.07M	45.57M	40.05M	38.61M	34.56M	33.34M	32.27M	27.59M
Adjusted Diluted Earnings per Share	($0.95)	($0.66)	($1.02)	$1.09	($1.14)	($0.94)	($0.62)	($0.83)	($1.05)	($0.97)	($0.61)
Adjusted Weighted Average Diluted Shares Outstanding	46.97M	46.31M	45.74M	46.04M	45.57M	40.05M	38.61M	34.56M	33.34M	32.27M	27.59M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($1.14)	($0.94)	($0.62)	($0.83)	($1.05)	($0.97)	($0.61)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	48.88M	95.18M	93.14M	46.03M	42.13M	37.59M	34.09M	32.39M	31.61M	28.06M	26.37M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-19	-30	-47	-31	-27	-12	-17	-22	-19	-11
Normalized NOPAT Margin	-6.02%	-4.68%	-9.04%	-17.18%	-15.11%	-11.54%	-5.95%	-10.01%	-14.05%	-14.41%	-10.66%
Pre Tax Income Margin	-9.39%	-7.48%	-13.98%	18.37%	-23.26%	-15.16%	-10.37%	-15.38%	-21.47%	-20.94%	-15.06%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-5.19	-3.86	-8.67	11.15	-9.06	-8.10	-3.76	-10.97	-17.61	-92.72	-52.36
NOPAT to Interest Expense	-3.61	-2.70	-5.99	11.18	-6.34	-5.64	-2.60	-7.72	-12.10	-64.05	-37.55
EBIT Less CapEx to Interest Expense	-6.66	-5.59	-12.05	9.17	-10.14	-11.05	-5.10	-13.79	-21.88	-138.76	-70.16
NOPAT Less CapEx to Interest Expense	-5.08	-4.43	-9.38	9.20	-7.42	-8.59	-3.95	-10.54	-16.37	-110.10	-55.35
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.24%	0.00%

This table displays calculated financial ratios and metrics derived from AtriCure's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	13.57%	16.64%	17.93%	15.21%	16.43%	21.03%	18.07%	19.39%	25.37%	20.23%	18.15%
EBITDA Growth	85.15%	-141.46%	44.11%	-479.55%	-160.57%	-523.99%	52.31%	95.72%	77.51%	92.64%	-107.69%
EBIT Growth	44.23%	-73.87%	12.34%	-67.33%	-95.12%	-120.89%	27.69%	69.01%	60.42%	69.18%	-111.45%
NOPAT Growth	45.46%	-67.55%	8.46%	-72.97%	-88.81%	-109.57%	24.56%	69.66%	59.14%	66.92%	-107.61%
Net Income Growth	49.15%	-59.04%	13.27%	-56.47%	-104.90%	-134.75%	26.21%	65.51%	57.35%	69.65%	-112.64%
EPS Growth	50.00%	-57.14%	15.00%	-54.55%	-100.00%	-110.00%	25.93%	65.63%	57.58%	64.29%	-112.80%
Operating Cash Flow Growth	47.54%	44.81%	1,214.32%	145.10%	-415.22%	8,660.87%	185.31%	-28.80%	83.44%	-84.72%	-668.97%
Free Cash Flow Firm Growth	88.53%	50.40%	92.12%	-17.16%	-6,331.09%	-10.62%	-216.99%	76.13%	100.82%	65.21%	12,696.25%
Invested Capital Growth	1.06%	2.78%	6.61%	9.36%	19.36%	10.24%	0.00%	9.12%	-1.50%	11.10%	0.00%
Revenue Q/Q Growth	-0.53%	7.22%	-0.31%	6.81%	2.17%	8.40%	-2.60%	7.94%	6.21%	5.74%	-1.52%
EBITDA Q/Q Growth	90.80%	-382.12%	17.76%	59.29%	-49.61%	-11.59%	-752.73%	81.70%	-258.27%	91.47%	23.49%
EBIT Q/Q Growth	59.26%	-110.71%	-0.07%	35.09%	-27.02%	-6.23%	-91.02%	24.30%	-43.80%	65.22%	18.15%
NOPAT Q/Q Growth	59.00%	-96.12%	-3.31%	34.34%	-25.95%	-7.16%	-95.20%	28.33%	-39.80%	61.43%	21.50%
Net Income Q/Q Growth	56.66%	-98.24%	1.94%	39.65%	-35.55%	-8.11%	-76.92%	20.97%	-55.30%	66.02%	17.31%
EPS Q/Q Growth	57.58%	-94.12%	0.00%	39.29%	-33.33%	-5.00%	-81.82%	21.43%	-40.00%	62.96%	15.63%
Operating Cash Flow Q/Q Growth	-288.93%	-70.83%	171.06%	135.12%	-621.49%	164.78%	-49.45%	173.82%	-8,967.39%	102.58%	-142.18%
Free Cash Flow Firm Q/Q Growth	59.45%	29.19%	25.78%	46.17%	-86.44%	88.75%	-1,003.26%	-2,962.90%	103.11%	-111.90%	325.06%
Invested Capital Q/Q Growth	3.40%	1.61%	-3.26%	-0.56%	5.84%	5.39%	-0.77%	8.54%	-2.87%	0.00%	-100.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	74.93%	74.53%	74.88%	74.69%	74.66%	74.91%	75.15%	76.38%	74.45%	73.97%	74.13%
EBITDA Margin	-0.75%	-8.14%	-1.81%	-2.19%	-5.75%	-3.93%	-3.82%	-0.44%	-2.57%	-0.76%	-9.45%
Operating Margin	-4.82%	-11.69%	-6.39%	-6.17%	-10.03%	-8.14%	-8.23%	-4.11%	-6.18%	-4.70%	-12.88%
EBIT Margin	-4.96%	-12.11%	-6.16%	-6.14%	-10.10%	-8.13%	-8.29%	-4.23%	-6.03%	-4.45%	-13.54%
Profit (Net Income) Margin	-5.46%	-12.53%	-6.78%	-6.89%	-12.19%	-9.19%	-9.21%	-5.07%	-6.93%	-4.74%	-14.74%
Tax Burden Percent	103.67%	101.74%	104.28%	103.26%	101.40%	103.96%	100.52%	101.85%	101.22%	102.99%	100.38%
Interest Burden Percent	106.10%	101.64%	105.40%	108.61%	118.97%	108.74%	110.51%	117.76%	113.50%	103.29%	108.46%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-3.91%	-9.58%	-5.21%	-4.73%	-7.68%	-6.08%	-11.79%	-2.93%	-4.35%	-3.22%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	2.38%	-1.40%	-1.86%	-0.45%	-0.36%	-1.84%	-4.33%	-0.72%	-2.15%	-2.25%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-0.21%	0.20%	0.32%	0.07%	0.06%	0.35%	0.85%	0.16%	0.52%	0.63%	0.00%
Return on Equity (ROE)	-4.12%	-9.38%	-4.89%	-4.66%	-7.62%	-5.73%	-10.94%	-2.77%	-3.82%	-2.58%	0.00%
Cash Return on Invested Capital (CROIC)	-6.98%	-9.79%	-12.62%	-15.16%	-23.53%	-14.74%	-208.34%	-13.55%	-5.39%	-19.35%	0.00%
Operating Return on Assets (OROA)	-4.03%	-9.22%	-4.54%	-4.43%	-7.13%	-5.41%	-5.26%	-2.62%	-3.61%	-2.45%	0.00%
Return on Assets (ROA)	-4.43%	-9.53%	-4.99%	-4.97%	-8.60%	-6.12%	-5.84%	-3.14%	-4.14%	-2.61%	0.00%
Return on Common Equity (ROCE)	-4.12%	-9.38%	-4.89%	-4.66%	-7.62%	-5.73%	-10.94%	-2.77%	-3.82%	-2.58%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-8.40%	0.00%	-8.37%	-8.68%	-8.16%	0.00%	-5.36%	-6.06%	-8.30%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.17	-10	-5.18	-5.02	-7.64	-6.07	-5.66	-2.90	-4.05	-2.90	-7.51
NOPAT Margin	-3.37%	-8.18%	-4.47%	-4.32%	-7.02%	-5.70%	-5.76%	-2.87%	-4.33%	-3.29%	-9.02%
Net Nonoperating Expense Percent (NNEP)	-6.28%	-8.17%	-3.35%	-4.28%	-7.33%	-4.25%	-7.47%	-2.21%	-2.19%	-0.96%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-0.81%	-1.93%	-	-	-	-1.15%	-	-	-	-0.55%	-
Cost of Revenue to Revenue	25.07%	25.47%	25.12%	25.31%	25.34%	25.09%	24.85%	23.62%	25.55%	26.03%	25.87%
SG&A Expenses to Revenue	61.52%	58.08%	63.19%	63.30%	66.46%	63.53%	62.68%	63.20%	64.24%	63.05%	68.79%
R&D to Revenue	18.22%	28.13%	18.08%	17.56%	18.23%	19.52%	20.71%	17.28%	16.39%	15.62%	18.22%
Operating Expenses to Revenue	79.75%	86.21%	81.27%	80.86%	84.69%	83.05%	83.38%	80.48%	80.64%	78.67%	87.01%
Earnings before Interest and Taxes (EBIT)	-6.13	-15	-7.15	-7.14	-11	-8.66	-8.15	-4.27	-5.64	-3.92	-11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-0.93	-10	-2.10	-2.55	-6.26	-4.19	-3.75	-0.44	-2.40	-0.67	-7.87
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.47	3.23	2.94	2.38	3.16	3.63	4.48	5.04	4.24	4.51	0.00
Price to Tangible Book Value (P/TBV)	9.53	8.78	7.94	6.59	9.04	10.10	12.77	14.55	10.64	11.28	0.00
Price to Revenue (P/Rev)	3.28	3.20	3.05	2.56	3.48	4.24	5.45	6.38	5.53	6.24	5.75
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.69	3.55	3.27	2.56	3.39	4.13	5.33	5.99	5.27	5.51	0.00
Enterprise Value to Revenue (EV/Rev)	3.21	3.08	2.90	2.44	3.37	4.05	5.21	6.14	5.21	5.93	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	69.34	117.33	124.74	0.00	0.00	360.70	3,966.13	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.14	0.14	0.13	0.13	0.14	0.14	0.09	0.10	0.11	0.16	0.00
Long-Term Debt to Equity	0.14	0.13	0.13	0.13	0.14	0.13	0.09	0.10	0.11	0.14	0.00
Financial Leverage	-0.09	-0.14	-0.17	-0.15	-0.17	-0.19	-0.20	-0.22	-0.24	-0.28	0.00
Leverage Ratio	1.30	1.32	1.31	1.29	1.29	1.30	1.30	1.29	1.27	1.28	0.00
Compound Leverage Factor	1.38	1.34	1.38	1.40	1.53	1.41	1.43	1.51	1.44	1.32	0.00
Debt to Total Capital	11.98%	12.30%	11.74%	11.81%	11.94%	11.93%	8.35%	9.23%	10.25%	13.53%	0.00%
Short-Term Debt to Total Capital	0.00%	0.53%	0.00%	0.00%	0.00%	0.48%	0.00%	0.00%	0.00%	1.04%	0.00%
Long-Term Debt to Total Capital	11.98%	11.77%	11.74%	11.81%	11.94%	11.45%	8.35%	9.23%	10.25%	12.49%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	88.02%	87.70%	88.26%	88.19%	88.06%	88.07%	91.65%	90.77%	89.75%	86.47%	0.00%
Debt to EBITDA	-3.94	-3.08	-4.10	-3.69	-4.22	-5.85	-5.80	-4.13	-2.45	-2.42	0.00
Net Debt to EBITDA	2.42	2.76	4.54	3.11	3.01	6.88	12.50	7.69	5.16	3.43	0.00
Long-Term Debt to EBITDA	-3.94	-2.94	-4.10	-3.69	-4.22	-5.62	-5.80	-4.13	-2.45	-2.24	0.00
Debt to NOPAT	-2.52	-2.31	-2.59	-2.54	-2.78	-3.38	-2.72	-2.71	-2.16	-2.39	0.00
Net Debt to NOPAT	1.55	2.07	2.86	2.14	1.98	3.97	5.86	5.05	4.56	3.39	0.00
Long-Term Debt to NOPAT	-2.52	-2.21	-2.59	-2.54	-2.78	-3.24	-2.72	-2.71	-2.16	-2.21	0.00
Altman Z-Score	7.10	6.17	5.65	5.07	6.53	7.03	9.17	10.75	9.16	9.69	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.11	3.65	3.62	4.13	4.00	3.57	3.06	3.33	3.82	3.69	0.00
Quick Ratio	2.67	2.49	2.49	2.77	2.63	2.55	2.24	2.46	2.91	2.81	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-8.55	-21	-30	-40	-74	-42	-378	-34	1.20	-38	323
Operating Cash Flow to CapEx	-505.55%	216.71%	554.43%	309.56%	-757.61%	144.65%	41.93%	97.76%	-163.03%	1.10%	-34.67%
Free Cash Flow to Firm to Interest Expense	-6.04	-14.52	-17.85	-24.88	-24.51	-23.63	-213.11	-19.91	0.73	-24.61	243.80
Operating Cash Flow to Interest Expense	-7.79	4.02	12.00	4.58	-6.92	2.24	0.86	1.75	-2.49	0.03	-1.35
Operating Cash Flow Less CapEx to Interest Expense	-9.33	2.17	9.84	3.10	-7.83	0.69	-1.19	-0.04	-4.02	-2.64	-5.23
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.81	0.76	0.74	0.72	0.71	0.67	0.63	0.62	0.60	0.55	0.00
Accounts Receivable Turnover	8.09	8.25	8.41	8.27	8.21	8.39	7.39	8.14	8.07	8.73	0.00
Inventory Turnover	1.65	1.64	1.63	1.68	1.70	1.74	1.54	1.91	1.99	1.99	0.00
Fixed Asset Turnover	11.53	0.00	10.54	10.40	10.16	0.00	9.20	9.55	9.64	0.00	0.00
Accounts Payable Turnover	4.47	4.50	4.01	4.29	3.90	4.19	3.87	3.89	4.07	4.39	0.00
Days Sales Outstanding (DSO)	45.10	44.26	43.40	44.11	44.45	43.51	49.40	44.84	45.21	41.82	0.00
Days Inventory Outstanding (DIO)	221.15	221.93	223.88	217.78	214.92	210.10	237.65	191.46	183.05	183.49	0.00
Days Payable Outstanding (DPO)	81.57	81.17	91.01	85.00	93.50	87.22	94.23	93.91	89.58	83.20	0.00
Cash Conversion Cycle (CCC)	184.68	185.02	176.27	176.89	165.87	166.40	192.82	142.39	138.68	142.11	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	417	403	397	410	412	392	372	375	345	356	0.00
Invested Capital Turnover	1.16	1.17	1.16	1.10	1.09	1.07	2.05	1.02	1.00	0.98	0.00
Increase / (Decrease) in Invested Capital	4.38	11	25	35	67	36	372	31	-5.24	36	-330
Enterprise Value (EV)	1,539	1,432	1,297	1,050	1,398	1,617	1,983	2,244	1,821	1,959	0.00
Market Capitalization	1,577	1,490	1,365	1,102	1,442	1,692	2,074	2,332	1,930	2,060	1,815
Book Value per Share	$9.30	$9.46	$9.55	$9.55	$9.77	$9.84	$9.77	$9.79	$9.77	$9.99	$0.00
Tangible Book Value per Share	$3.39	$3.48	$3.53	$3.45	$3.41	$3.53	$3.43	$3.39	$3.90	$3.99	$0.00
Total Capital	516	526	527	524	518	529	505	509	507	528	0.00
Total Debt	62	65	62	62	62	63	42	47	52	71	0.00
Total Long-Term Debt	62	62	62	62	62	61	42	47	52	66	0.00
Net Debt	-38	-58	-68	-52	-44	-74	-91	-88	-109	-101	0.00
Capital Expenditures (CapEx)	2.18	2.69	3.61	2.38	2.77	2.79	3.63	3.08	2.50	4.17	5.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	90	74	65	78	78	57	37	40	40	41	0.00
Debt-free Net Working Capital (DFNWC)	190	197	195	192	184	194	170	167	176	162	0.00
Net Working Capital (NWC)	190	194	195	192	184	192	170	167	176	157	0.00
Net Nonoperating Expense (NNE)	2.58	5.40	2.67	2.99	5.63	3.72	3.39	2.22	2.43	1.27	4.77
Net Nonoperating Obligations (NNO)	-38	-58	-68	-52	-44	-74	-91	-88	-109	-101	0.00
Total Depreciation and Amortization (D&A)	5.20	4.95	5.05	4.59	4.74	4.47	4.40	3.83	3.23	3.25	3.40
Debt-free, Cash-free Net Working Capital to Revenue	18.83%	16.01%	14.42%	18.05%	18.82%	14.26%	9.76%	10.81%	11.45%	12.46%	0.00%
Debt-free Net Working Capital to Revenue	39.63%	42.38%	43.54%	44.57%	44.37%	48.64%	44.70%	45.55%	50.35%	49.12%	0.00%
Net Working Capital to Revenue	39.63%	41.78%	43.54%	44.57%	44.37%	48.01%	44.70%	45.55%	50.35%	47.47%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.14)	($0.33)	($0.17)	($0.17)	($0.28)	($0.21)	($0.20)	($0.11)	($0.14)	($0.10)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	47.39M	46.97M	47.11M	46.91M	46.72M	46.31M	46.41M	46.27M	46.11M	45.74M	0.00
Adjusted Diluted Earnings per Share	($0.14)	($0.33)	($0.17)	($0.17)	($0.28)	($0.21)	($0.20)	($0.11)	($0.14)	($0.10)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	47.39M	46.97M	47.11M	46.91M	46.72M	46.31M	46.41M	46.27M	46.11M	45.74M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.50M	48.88M	48.75M	48.70M	48.38M	95.18M	47.40M	47.35M	47.24M	93.14M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-4.17	-10	-5.18	-5.02	-7.64	-6.07	-5.66	-2.90	-4.05	-2.90	-7.51
Normalized NOPAT Margin	-3.37%	-8.18%	-4.47%	-4.32%	-7.02%	-5.70%	-5.76%	-2.87%	-4.33%	-3.29%	-9.02%
Pre Tax Income Margin	-5.26%	-12.31%	-6.50%	-6.67%	-12.02%	-8.84%	-9.16%	-4.98%	-6.84%	-4.60%	-14.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.33	-10.38	-4.29	-4.43	-3.62	-4.82	-4.60	-2.48	-3.45	-2.51	-8.51
NOPAT to Interest Expense	-2.94	-7.01	-3.11	-3.11	-2.51	-3.37	-3.20	-1.69	-2.47	-1.85	-5.67
EBIT Less CapEx to Interest Expense	-5.87	-12.23	-6.45	-5.91	-4.53	-6.37	-6.65	-4.27	-4.97	-5.18	-12.40
NOPAT Less CapEx to Interest Expense	-4.48	-8.86	-5.27	-4.59	-3.43	-4.92	-5.24	-3.48	-4.00	-4.53	-9.56
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About AtriCure's Financials

When does AtriCure's fiscal year end?

According to the most recent income statement we have on file, AtriCure's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AtriCure's net income changed over the last 10 years?

AtriCure's net income appears to be on an upward trend, with a most recent value of -$44.70 million in 2024, rising from -$16.21 million in 2014. The previous period was -$30.44 million in 2023. Find out what analysts predict for AtriCure in the coming months.

What is AtriCure's operating income?

AtriCure's total operating income in 2024 was -$40.01 million, based on the following breakdown:

Total Gross Profit: $347.52 million
Total Operating Expenses: $387.54 million

How has AtriCure revenue changed over the last 10 years?

Over the last 10 years, AtriCure's total revenue changed from $107.45 million in 2014 to $465.31 million in 2024, a change of 333.0%.

How much debt does AtriCure have?

AtriCure's total liabilities were at $148.36 million at the end of 2024, a 0.4% increase from 2023, and a 473.6% increase since 2014.

How much cash does AtriCure have?

In the past 10 years, AtriCure's cash and equivalents has ranged from $21.81 million in 2017 to $122.72 million in 2024, and is currently $122.72 million as of their latest financial filing in 2024.

How has AtriCure's book value per share changed over the last 10 years?

Over the last 10 years, AtriCure's book value per share changed from 4.82 in 2014 to 9.46 in 2024, a change of 96.0%.

Related Companies

This page (NASDAQ:ATRC) was last updated on 5/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AtriCure (ATRC) Financials

Frequently Asked Questions About AtriCure's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AtriCure (ATRC) Financials

Annual Income Statements for AtriCure

Quarterly Income Statements for AtriCure

Annual Cash Flow Statements for AtriCure

Quarterly Cash Flow Statements for AtriCure

Annual Balance Sheets for AtriCure

Quarterly Balance Sheets for AtriCure

Annual Metrics And Ratios for AtriCure

Quarterly Metrics And Ratios for AtriCure

Frequently Asked Questions About AtriCure's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools